DxS Grants DuPont Qualicon License to Scorpions Technology for Food and Beverage Diagnostics
DxS Ltd, a personalized medicine company and leader in the provision of companion diagnostics, has granted DuPont Qualicon, a developer of innovative, science-based diagnostic products that can reduce the impact of pathogens and other unwelcome organisms in food and pharmaceuticals, a license to use its novel Scorpions® diagnostic platform to develop tests for use by the food industry. Financial terms were not disclosed.
The deal will allow DuPont Qualicon to use DxS Scorpions® technology, a highly sensitive and adaptable platform, to develop rapid multiplex assays for detecting microorganisms that affect food safety and quality. Scorpions® is a homogeneous, closed-tube platform for PCR analysis for which DxS own the worldwide IP. The technology provides an accurate, rapid and reliable fluorescence-based signal generation system with application rights in in vitro diagnostics, genetic analysis, biothreat detection, environmental utility and now also food and drink microbial testing.
“With Scorpions® cutting-edge technology, we can develop increasingly faster, more sensitive tests for pathogens and spoilage organisms that anticipate and satisfy the evolving needs of the food industry for safer, higher quality products,” said Kevin Huttman, president - DuPont Qualicon.
“Scorpions® has unparalleled sensitivity and specificity making it ideal for detecting often difficult to find organisms which may not be identifiable through other diagnostic platforms,” said Stephen Little, CEO of DxS. “We are very pleased to have concluded this deal with DuPont Qualicon, which serves to highlight the benefits of the Scorpions® platform including increased speed, accuracy and applicability.”
DxS is a personalized medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. Working in partnership with pharmaceutical companies to support the development and sales of targeted cancer therapies by providing biomarkers and companion diagnostics.
DxS has a continually expanding portfolio of cancer mutation products. The TheraScreen range of CE-marked clinical diagnostic kits can identify genetic tumor mutations that affect how patients respond to cancer therapies, thus enabling doctors to provide the most beneficial treatment. DxS produces two clinical diagnostic kits, K-RAS and EGFR29.
The TheraScreen: K-RAS Mutation kit is a companion diagnostic for Vectibix® (Amgen) and Erbitux® (Merck KGaA) for the treatment of colorectal cancer. DxS has an exclusive global distribution agreement with Roche Diagnostics for the distribution of the TheraScreen: K-RAS and TheraScreen: EGFR29 Mutation kits.
DxS’ pioneering real-time PCR technology Scorpions® is highly regarded for its proven speed and sensitivity, and is combined with ARMS (allele specific PCR) to develop each unique DxS product. This class-leading technology is also available for license to diagnostic companies for research or for other varied applications.
DxS is a private, venture capital-backed company operating from the heart of Manchester’s Technology Quarter in the U.K. For further information please visit www.dxsdiagnostics.com.
Food processing companies around the world rely on the BAX® system to detect pathogens or other organisms in raw ingredients, finished products and environmental samples. The automated system uses leading-edge technology, including PCR assays, tableted reagents and optimized media also to detect Salmonella, Listeria monocytogenes, E. coli O157:H7, Campylobacter, and more. With certifications and regulatory approvals in the Americas, Asia and Europe, the BAX® system is recognized globally as the most advanced pathogen testing system available to food companies. DuPont Qualicon also markets the RiboPrinter® system, an automated method for identifying bacteria and pinpointing the contamination source. For more information and photos, please visit www.qualicon.com.
DuPont is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 70 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.